from:https://clinicaltrials.gov/ct2/show/NCT02237846
NLM
Identifier:
NCT02237846.
30. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of
rheumatoid arthritis, based on the 1987 American College of Rheumatology
criteria: a systematic review. Semin Arthritis Rheum. 2006; 36(3): 182-8.
31. Carmona L, Cross M, Williams B, Lassere M, March L. Rheumatoid
arthritis. Best Pract Res Clin Rheumatol. 2010; 24(6): 733-745.
32. Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract
Res Clin Rheumatol. 2007; 21(5): 885-906.
33. Bansard C, Lequerré T, Daveau M, et al. Can rheumatoid arthritis
responsiveness to methotrexate and biologics be predicted? Rheumatology
(Oxford). 2009; 48(9): 1021-1028.
34. Hoogduijn MJ, Crop MJ, Peeters AM, et al. Human heart, spleen, and
perirenal fat-derived mesenchymal stem cells have immunomodulatory
capacities. Stem Cells Dev. 2007; 16(4): 597-604.
35. English K, Barry FP, Mahon BP. Murine mesenchymal stem cells
suppress dendritic cell migration, maturation and antigen presentation. Immunol
Lett. 2008; 115(1): 50-8.
36. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus
regenerative medicine. J Cell Physiol. 2007; 213(2): 341-347.
37. La Rocca G, Lo Iacono M, Corsello T, Corrao S, Farina F, Anzalone R.
Human Wharton’s jelly mesenchymal stem cells maintain the expression of key
immunomodulatory molecules when subjected to osteogenic, adipogenic and
chondrogenic differentiation in vitro: new perspectives for cellular therapy. Curr
Stem Cell Res Ther. 2013; 8(1): 100-13.
38. Liang J, Zhang H, Hua B, et al. Allogenic mesenchymal stem cells
transplantation in refractory systemic lupus erythematosus: a pilot clinical study.
Ann Rheum Dis. 2010; 69(8): 1423-9.
39. Sun L, Wang D, Liang J, et al. Umbilical cord mesenchymal stem cell
transplantation in severe and refractory systemic lupus erythematosus. Arthritis
